DE69811087T2 - Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine - Google Patents

Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine

Info

Publication number
DE69811087T2
DE69811087T2 DE1998611087 DE69811087T DE69811087T2 DE 69811087 T2 DE69811087 T2 DE 69811087T2 DE 1998611087 DE1998611087 DE 1998611087 DE 69811087 T DE69811087 T DE 69811087T DE 69811087 T2 DE69811087 T2 DE 69811087T2
Authority
DE
Germany
Prior art keywords
hpv
contain
compositions
cells
stress protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE1998611087
Other languages
English (en)
Other versions
DE69811087D1 (de
Inventor
Lee Mizzen
Randall Chu
Huacheng Bill Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stressgen Biotechnologies Corp
Original Assignee
Stressgen Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21993829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69811087(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stressgen Biotechnologies Corp filed Critical Stressgen Biotechnologies Corp
Publication of DE69811087D1 publication Critical patent/DE69811087D1/de
Application granted granted Critical
Publication of DE69811087T2 publication Critical patent/DE69811087T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE1998611087 1997-08-05 1998-03-20 Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine Expired - Lifetime DE69811087T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5483597P 1997-08-05 1997-08-05
PCT/CA1998/000246 WO1999007860A1 (en) 1997-08-05 1998-03-20 Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins

Publications (2)

Publication Number Publication Date
DE69811087D1 DE69811087D1 (de) 2003-03-06
DE69811087T2 true DE69811087T2 (de) 2003-05-22

Family

ID=21993829

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1998634671 Expired - Lifetime DE69834671T2 (de) 1997-08-05 1998-03-20 Immunantwort gegen HPV Antigene hervorgerufen von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einem Expressionsvektor fähig zur Expression dieser Proteine
DE1998611087 Expired - Lifetime DE69811087T2 (de) 1997-08-05 1998-03-20 Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1998634671 Expired - Lifetime DE69834671T2 (de) 1997-08-05 1998-03-20 Immunantwort gegen HPV Antigene hervorgerufen von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einem Expressionsvektor fähig zur Expression dieser Proteine

Country Status (19)

Country Link
US (4) US6524825B1 (de)
EP (1) EP1002110B2 (de)
JP (2) JP4198315B2 (de)
KR (2) KR100843109B1 (de)
CN (3) CN100489105C (de)
AT (2) ATE231917T1 (de)
AU (1) AU6492498A (de)
BR (1) BR9812272A (de)
CA (1) CA2298840A1 (de)
DE (2) DE69834671T2 (de)
DK (1) DK1002110T3 (de)
ES (2) ES2191929T3 (de)
HK (2) HK1028981A1 (de)
HU (1) HUP0003601A3 (de)
IL (1) IL134341A0 (de)
NZ (3) NZ538399A (de)
PL (1) PL196805B1 (de)
PT (2) PT1002110E (de)
WO (1) WO1999007860A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221488A1 (de) 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Stressproteine und ihre Verwendung
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
ES2191929T3 (es) * 1997-08-05 2003-09-16 Stressgen Biotechnologies Corp Respuestas inmunologicas contra los antigenos pvh estimuladas por composiciones que comprenden un antigeno pvh y una proteina de estres o un vector de expresion capaz de expresar dichas proteinas.
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP1216055A2 (de) 1999-09-30 2002-06-26 Corixa Corporation Stress protein zusammensetzungen und verfahren zur vorbeugung ung behandlung von krebs und infektionskrankheiten
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
EP1222289B1 (de) * 1999-10-20 2008-04-16 The Johns Hopkins University School Of Medicine Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DE60042704D1 (de) * 2000-01-14 2009-09-17 Whitehead Biomedical Inst Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
CA2408830A1 (en) * 2000-05-12 2001-11-22 The Regents Of The University Of California Treatment of human papillomavirus (hpv)-infected cells
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
AU2001278117A1 (en) * 2000-08-03 2002-02-18 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
CN100400099C (zh) * 2001-01-04 2008-07-09 北京迪威华宇生物技术有限公司 预防和治疗人前列腺癌的重组蛋白疫苗
WO2002061113A2 (en) * 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2002062959A2 (en) 2001-02-05 2002-08-15 Stressgen Biotechnologies Corp. Hepatitis b virus treatment
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
KR100785397B1 (ko) * 2001-06-28 2007-12-13 아피메즈 주식회사 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
KR100474114B1 (ko) * 2001-12-24 2005-03-08 대한민국 소 타일레리아병에 대한 면역원성이 증진된 융합단백질, 및 그의 제조방법 및 용도
WO2007095318A2 (en) 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Influenza antigens, vaccine compositions, and related methods
US7763259B2 (en) * 2003-01-10 2010-07-27 The Regents Of The University Of Colorado Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection
US7211257B2 (en) * 2003-02-10 2007-05-01 Rosalind Franklin University Of Medicine And Science Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody
WO2004098526A2 (en) 2003-05-05 2004-11-18 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
EP1664322B1 (de) 2003-05-22 2013-07-10 Fraunhofer USA, Inc. Rekombinantes trägermolekül zur expression, zuführung und reinigung von zielpolypeptiden
EP2289547B1 (de) 2003-09-12 2015-12-16 Agenus Inc. Impfstoff zur Behandlung und Prävention der Herpes Simplex-Virusinfektion
US7304139B2 (en) * 2003-10-28 2007-12-04 University Of Florida Research Foundation, Inc. Polynucleotides and polypeptides of Anaplasma phagocytophilum and methods of using the same
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
CN1727362B (zh) * 2004-07-30 2010-12-01 中国人民解放军第二军医大学 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用
CN1769298B (zh) * 2004-11-05 2010-04-07 中国人民解放军军事医学科学院生物工程研究所 一种具有抗肿瘤作用的融合蛋白及其编码基因与应用
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
CN1299769C (zh) * 2005-01-31 2007-02-14 中国医学科学院肿瘤医院肿瘤研究所 人乳头瘤病毒和热休克蛋白重组蛋白疫苗及其用途
CA2609927A1 (en) * 2005-04-27 2006-11-02 Leiden University Medical Center Methods and means for the treatment of hpv induced intraepithelial neoplasias
US8962278B2 (en) 2005-08-03 2015-02-24 Ibio Inc. Compositions and methods for production of immunoglobulins
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007038083A2 (en) * 2005-09-21 2007-04-05 New York University Heat shock proteins from mycobacterium leprae and uses thereof
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
US8277816B2 (en) * 2006-02-13 2012-10-02 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
EP1984388B1 (de) * 2006-02-13 2016-07-06 iBio, Inc. Hpv-antigene, impfstoffzusammensetzungen und zugehörige verfahren
BRPI0712729A2 (pt) * 2006-05-31 2013-07-02 Nventa Biopharmaceuticals Corp composiÇÕes hspe7 bioativas purificadas
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20100003704A1 (en) * 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
AU2007353773A1 (en) * 2006-12-22 2008-11-27 Dow Agrosciences Llc Plant-made West Nile virus (WNV) vaccines, vectors and plant codon optimized sequences
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
WO2008124483A1 (en) * 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
CA2685558A1 (en) * 2007-04-28 2008-11-06 Fraunhofer Usa, Inc. Trypanosoma antigens, vaccine compositions, and related methods
US8088392B2 (en) * 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
CN101952320B (zh) * 2007-06-18 2013-08-14 上海泽润安珂生物制药有限公司 具有免疫原性的物质
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
CU23674A1 (es) 2007-07-31 2011-05-27 Ct Ingenieria Genetica Biotech Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica
WO2009026397A2 (en) * 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
WO2009127988A1 (en) * 2008-04-16 2009-10-22 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2009129502A2 (en) 2008-04-18 2009-10-22 The General Hospital Corporation Immunotherapies employing self-assembling vaccines
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8580270B2 (en) * 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
JP2012526286A (ja) 2009-05-07 2012-10-25 オンコヘルス コーポレーション ヒトパピローマウイルス（ｈｐｖ）およびｈｐｖ関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧ｃｉｎ２の同定
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
WO2011084598A1 (en) 2010-01-08 2011-07-14 Oncohealth Corporation High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
WO2011115688A2 (en) 2010-03-19 2011-09-22 H. Lee Moffitt Cancer Center & Research Institute Integrin interaction inhibitors for the treatment of cancer
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
EP2734231A1 (de) * 2011-07-21 2014-05-28 Biotech Tools S.A. Dosierung von dnak
US9993534B2 (en) 2013-03-12 2018-06-12 Wisconsin Alumni Research Foundation Method of treating fungal infection
RU2537233C2 (ru) * 2013-03-26 2014-12-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кабардино-Балкарский государственный университет им. Х.М. Бербекова" (КБГУ) Применение комплекса антиоксидантных витаминов и аминокислот в качестве дополнения к стандартным методам терапии и способ лечения папилломавирус-ассоциированных предраковых заболеваний шейки матки и профилактики канцерогенеза при папилломавирусной инфекции
US9663556B2 (en) 2013-10-04 2017-05-30 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
FR3011850B1 (fr) * 2013-10-15 2018-04-06 Cfl Biotech Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes
RU2017132190A (ru) * 2015-03-18 2019-04-18 Омнисайт Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними
WO2017015504A1 (en) 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
CN108484776B (zh) * 2018-03-19 2019-11-05 首都医科大学附属北京朝阳医院 一种融合蛋白、制备方法及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550405A (en) * 1895-11-26 Island
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
IL71683A0 (en) 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
US4906742A (en) 1986-07-31 1990-03-06 Whitehead Institute For Biomedical Research Encoding antigens of M. Leprae
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
NL8701163A (nl) 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
EP0345299A1 (de) 1987-02-02 1989-12-13 Whitehead Institute For Biomedical Research Mycobacterium tuberculosis-gene, kodierend für proteinantigene
US4952395A (en) 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US4918166A (en) 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
NL8703107A (nl) 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
CA1338778C (en) 1988-06-15 1996-12-10 Richard A. Young Stress proteins and uses therefor
US5114844A (en) 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
EP0478664B1 (de) 1989-06-19 2003-09-17 Whitehead Institute For Biomedical Research Verktorvermittelte genominsertion und expression von dna in bcg
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
DE69126668T2 (de) 1990-11-08 1997-10-23 Univ London Mycobacterium als adjuvans für antigene
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
GB2251186A (en) 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
GB9211736D0 (en) 1992-06-03 1992-07-15 Univ Cardiff Allergic treatment
US5736146A (en) 1992-07-30 1998-04-07 Yeda Research And Development Co. Ltd. Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
JP2541081B2 (ja) * 1992-08-28 1996-10-09 日本電気株式会社 バイオセンサ及びバイオセンサの製造・使用方法
EP1221488A1 (de) 1993-06-04 2002-07-10 Whitehead Institute For Biomedical Research Stressproteine und ihre Verwendung
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL109790A0 (en) * 1994-05-25 1994-08-26 Yeda Res & Dev Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
US5955087A (en) * 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
CA2229543A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
CA2231998A1 (en) 1995-09-13 1997-03-20 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
US6130087A (en) 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
DK0941315T3 (da) 1996-11-26 2006-05-15 Stressgen Biotechnologies Corp Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
CA2282426A1 (en) 1997-02-18 1998-08-20 The Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
ES2191929T3 (es) * 1997-08-05 2003-09-16 Stressgen Biotechnologies Corp Respuestas inmunologicas contra los antigenos pvh estimuladas por composiciones que comprenden un antigeno pvh y una proteina de estres o un vector de expresion capaz de expresar dichas proteinas.
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP2003504074A (ja) * 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのＴｈ１様応答の誘導

Also Published As

Publication number Publication date
AU6492498A (en) 1999-03-01
PL338478A1 (en) 2000-11-06
PL196805B1 (pl) 2008-02-29
US20080050399A1 (en) 2008-02-28
ATE231917T1 (de) 2003-02-15
CN1680451A (zh) 2005-10-12
PT1336621E (pt) 2006-08-31
ATE327259T1 (de) 2006-06-15
EP1002110A1 (de) 2000-05-24
DE69811087D1 (de) 2003-03-06
US6524825B1 (en) 2003-02-25
EP1002110B1 (de) 2003-01-29
NZ522653A (en) 2005-03-24
ES2191929T3 (es) 2003-09-16
IL134341A0 (en) 2001-04-30
CN1270635A (zh) 2000-10-18
DE69834671D1 (de) 2006-06-29
DK1002110T3 (da) 2003-05-26
US6900035B2 (en) 2005-05-31
HK1058367A1 (en) 2004-05-14
HK1028981A1 (en) 2001-03-16
CN100489105C (zh) 2009-05-20
DE69834671T2 (de) 2007-05-10
HUP0003601A3 (en) 2003-03-28
JP2006001939A (ja) 2006-01-05
KR100843109B1 (ko) 2008-07-02
CA2298840A1 (en) 1999-02-18
NZ502568A (en) 2003-01-31
KR20060111731A (ko) 2006-10-27
US7262014B2 (en) 2007-08-28
US20030148456A1 (en) 2003-08-07
BR9812272A (pt) 2000-07-18
JP2001512749A (ja) 2001-08-28
KR20010022637A (ko) 2001-03-26
PT1002110E (pt) 2003-06-30
US20050037017A1 (en) 2005-02-17
EP1002110B2 (de) 2009-07-29
WO1999007860A1 (en) 1999-02-18
ES2266652T3 (es) 2007-03-01
HUP0003601A2 (hu) 2001-02-28
NZ538399A (en) 2007-05-31
JP4198315B2 (ja) 2008-12-17
CN1915425A (zh) 2007-02-21

Similar Documents

Publication Publication Date Title
DE69811087T2 (de) Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
MA24638A1 (fr) Vaccin
EP1847549A3 (de) Polyproteinkonstrukte des Papillomavirus
MXPA05008128A (es) Peptidos derivados de survivina y uso de los mismos.
WO2002080851A3 (en) Chimeric vaccines
Sedlik et al. Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms
DK1278534T3 (da) Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
EP1829552A3 (de) Chlamydia-PMP-Proteine, Gensequenzen und ihre Verwendung
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
EP1499349A4 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
AP2368A (en) Novel expression vectors and uses thereof.
EP1336621A3 (de) Immunresponse gegen HPV Antigene erregt von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einen Expressionsvektor fähig zur Expression dieser Proteine
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
ATE346926T1 (de) Menschliche twik-8 moleküle und ihre verwendung
WO2002059314A3 (en) A human melanoma associated antigen and uses therefor
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
NZ334582A (en) Polyprotein construct of a papillomavirus

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8332 No legal effect for de